Zobrazeno 1 - 10
of 26
pro vyhledávání: '"D. M. Kramsch"'
Autor:
D H Blankenhorn, Clinton N. Corder, Carolyn Knight-Gibson, P. Alaupovic, D M Kramsch, W. J. Mack, L LaBree, H. N. Hodis, L. Cashin-Hemphill
Publikováno v:
Arteriosclerosis and Thrombosis: A Journal of Vascular Biology. 14:1906-1913
To establish whether lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, exhibits a specific effect on apolipoprotein (apo) A- and apoB-containing lipoproteins, 63 subjects, a subset of the 270 Monitored Atheroscler
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::814840f4d36eb5d30eff498de9e17028
https://doi.org/10.1161/01.atv.14.12.1906
https://doi.org/10.1161/01.atv.14.12.1906
Autor:
D. M. Kramsch
Publikováno v:
Developments in Cardiovascular Medicine ISBN: 9789401065511
MARS and other angiographic trials revealed that aggressive LDL-cholesterol reduction regressed only advanced fibrous—fatty plaques while younger cell proliferative lesions progressed further. We, therefore, tested the antioxidant/antiproliferant C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fda2dc51b68ece9674a9a6e449c3392f
https://doi.org/10.1007/978-94-009-0143-8_12
https://doi.org/10.1007/978-94-009-0143-8_12
Autor:
D M, Kramsch
Publikováno v:
Atherosclerosis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aa59d1bee4ce999e9d6ec377ffd81e46
https://pubmed.ncbi.nlm.nih.gov/8821462
https://pubmed.ncbi.nlm.nih.gov/8821462
Autor:
D M, Kramsch, R C, Sharma
Publikováno v:
Journal of human hypertension. 9
Treatment of atherosclerosis has mainly focused on decreasing low-density lipoprotein cholesterol (LDL-C). However, recent coronary angiographic trials revealed that aggressive lowering of LDL-C below 100 mg/dl arrests atherosclerosis progression in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::239b99e054bd47a3de16fc7af7c10d15
https://pubmed.ncbi.nlm.nih.gov/7783112
https://pubmed.ncbi.nlm.nih.gov/7783112
Autor:
Howard N. Hodis, D M Kramsch, L I Vailas, L J Hirsch, Stanley P. Azen, Linda Cashin-Hemphill, M J Masteller, Petar Alaupovic, David H. Blankenhorn, Wendy J. Mack, L W DeBoer, Peter R. Mahrer
Publikováno v:
Annals of internal medicine. 119(10)
To assess the effects of lipid-lowering therapy with lovastatin on coronary angiographic findings in patients with coronary artery disease and to compare the findings with those of two lipid-lowering angiographic trials using similar end points.Rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::346dfd3179d92e38b6b0ebd35ae01aa1
https://pubmed.ncbi.nlm.nih.gov/8147558
https://pubmed.ncbi.nlm.nih.gov/8147558
Publikováno v:
Drugs Affecting Lipid Metabolism ISBN: 9789401047463
A minor, more electronegatively charged, sub-fraction (LDL-) was isolated from plasma LDL by ion exchange HPLC and characterized as a mildly oxidized LDL. In samples obtained from normal donors HPLC analysis of OPA derivatized amino-acids, reverse ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73035e724e1f38afdcdf4807b327ce52
https://doi.org/10.1007/978-94-011-1703-6_25
https://doi.org/10.1007/978-94-011-1703-6_25
Autor:
L, Cashin-Hemphill, D M, Kramsch, S P, Azen, D, DeMets, L W, DeBoer, I, Hwang, L, Vailas, L J, Hirsch, W J, Mack, L, DeBoer
Publikováno v:
The Online journal of current clinical trials.
The Monitored Atherosclerosis Regression Study (MARS) was designed to evaluate the effect of cholesterol lowering by monotherapy with an HMG-CoA reductase inhibitor on progression/regression of atherosclerosis in subjects with angiographically docume
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f5a88120671ceea4353edff3ff0b22e
https://pubmed.ncbi.nlm.nih.gov/1343613
https://pubmed.ncbi.nlm.nih.gov/1343613
Autor:
D M, Kramsch, D H, Blankenhorn
Publikováno v:
Wiener klinische Wochenschrift. 104(1)
Two major features of atherosclerosis may be distinguished: (a) atherosis caused by lipid infiltration in cells and extracellularly and (b) sclerosis caused by connective tissue deposition and by functional disturbance of the endothelium, leading to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6687ca6e2050b646e26270dc861c7cbb
https://pubmed.ncbi.nlm.nih.gov/1546480
https://pubmed.ncbi.nlm.nih.gov/1546480
Autor:
Janet E. Rush, F. Moncloa, J. F. Walker, M. A. Gabriel, W. McFate Smith, R. O. Davies, D. M. Kramsch
Publikováno v:
British Journal of Clinical Pharmacology. 18:249S-255S
Enalapril is the result of a targeted research programme to develop a non-mercapto converting enzyme inhibitor with a long duration of action and an improved safety profile for use in the therapy of hypertension and congestive heart failure. Over 350
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4be7ebad4b896da70d396158e8f63a2f
https://doi.org/10.1111/j.1365-2125.1984.tb02604.x
https://doi.org/10.1111/j.1365-2125.1984.tb02604.x